跳至主要内容
临床试验/EUCTR2011-003933-32-GB
EUCTR2011-003933-32-GB进行中(未招募)不适用

A randomised, blind, placebo controlled crossover study of the influence of the HCN channel-blocker ivabradine on the symptoms of neuropathic pain - The influence of ivabradine on the symptoms of neuropathic pain IISNeP

Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge0 个研究点目标入组 12 人开始时间: 2011年9月8日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Volunteers who have given written, informed consent to participate. - Volunteers who can communicate fluently in English.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 12
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • - Volunteers not giving consent to participate. - Volunteers who cannot communicate fluently in English. - Volunteers with 1 arm - Volunteers who are allergic to ivabradine, capsaicin or Tegaderm. - Volunteers for whom ivabradine is contraindicated: namely sick sinus syndrome and concomitant use of CYP3A4 inhibitors such as ketoconazole, macrolide antibiotics, nefazodone and the anti-retrovirals nelfinavir and ritonavir. - Volunteers with any rash or broken skin on the forearm where capsaicin will be applied. - Volunteers with lactose intolerance. - Volunteers with a resting pulse rate of 59 beats per minute or less at screening or on the day of the study. - Volunteers who are pregnant - Volunteers who have any underlying medical condition such as migraine or epilepsy which may affect the study findings - Volunteers who smoke, take recreational drugs or consume more than the recommended allowance of alcohol units per week

研究者

发起方
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge

相似试验

The Influence of Ivabradine on the Symptoms of... | 临床试验